Funding tracker
UFORCE raised $700M
$700MRaised
Series AStage
12 Nov 2026Date
2.6KViews on the announcement
The round
| Amount | $700M |
|---|---|
| Stage | Series A |
| Valuation | $6B |
| Investors | not stated |
| What they do | Ukrainian defence technology company |
| Vertical | Space and defense |
| First reported | Thursday, 12 November 2026 |
The announcement on X
The median tracked announcement from accounts with under 10K followers reached 13.4K views (201 posts). This one did 0.20x that.
Excited to finally share that UFORCE has raised a $700M Series A at a $6B valuation. Proud of this company and what our teams have accomplished in such a short period of time. Most importantly, I'm proud of our teams in Ukraine, who have built and deployed world-chaning technology under circumstances most of us can barely imagine. What began as innovation born out of the necessity to survive on Ukraine's front lines is now being recognized by Western allies as a critical component of their own future defense and national security. Our job is to support them and bring those combat-proven capabilities to allied nations at scale. We're building an exceptional global team to help us execute on this mission, and I'm personally hiring across a number of functions: - Business Operations - Program / Project Management - People & Talent - GTM/G&A AI - Product Marketing - Creative - Field - + more Join us and change the world -- https://t.co/u8uWlyDHJa
| Posted by | @thec00z (Zach Cusimano) |
|---|---|
| Followers | 1,028 |
| Views | 2,630 |
| Views per follower | 2.6x |
| Likes | 6 |
| Reposts | 1 |
| Bookmarks | 1 |
Similar rounds
| Company | Stage | Amount | Lead | On X | Date |
|---|---|---|---|---|---|
| MirendilDemocratizing frontier AI R&D | Series A | $1B | - | 222.2K | 12 Nov 2026 |
| Orakl OncologyAI predicting effective cancer drugs | Series A | €30M | - | - | 12 Nov 2026 |
| SE3Spatial intelligence for military drones | Series A | $30M | - | - | 12 Nov 2026 |
| Hatz AISells AI through MSPs | Series A | $24M | - | - | 12 Nov 2026 |
| NebulyMeasures economic value of enterprise AI agents | Series A | $21M | - | - | 12 Nov 2026 |
| BiomatterAI-designed custom enzymes | Series A | $18M | - | - | 12 Nov 2026 |
Next launch
Planning a launch?
Tell us what is launching and when. Thirty minutes is usually enough to know whether we are the right team for it.